Cencora (COR) Stock Nosedives: Here's What Caused the Decline
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court
Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora: Long-Term Compounder With Mouth-Watering Economics
COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working capital benefits. I have updated my price objectives to $270-$285 with a long-term intrinsic valuation of over $360 per share.
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora notifies individuals about data stolen earlier this year
U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the company said on Friday.
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Walgreens Sells Another Stake In Distributor Cencora For $400 Million
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $400 million, which will be used for “debt paydown and general corporate purposes.”
Cencora to buy $400 million in stock back from Walgreens
Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash to pare down debt.
Camino and Rio Tinto Both Acquire New Claims at Auction Nar the Los Chapitos Copper Project in Peru
VANCOUVER, BC / ACCESSWIRE / May 17, 2024 / Camino Corp. (TSXV:COR)(OTC PINK:CAMZF)(WKN:A116E1) ("Camino" or the "Company") is pleased to announce that it has increased its claims at its Los Chapitos copper property ("Los Chapitos" or the "Project") by an additional 1,700 hectares. In a land auction, Camino successfully competed against other bidders that included Rio Tinto, to gain titles to new exploration claims immediately adjacent to the Company's Los Chapitos copper claims.
